EMG
NKTR icon

Ellington Management Group’s Nektar Therapeutics NKTR Stock Holding History

Ellington Management Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,307
Closed -$1.16M – 818
2017
Q1 		$1.16M Buy
+3,307
New +$743K 0.04% 64
2015
Q1 		– Sell
-1,367
Closed -$318K – 771
2014
Q4 		$318K Sell
1,367
-2,526
-65% -$540K 0.11% 319
2014
Q3 		$705K Buy
3,893
+2,800
+256% +$536K 0.48% 24
2014
Q2 		$210K Sell
1,093
-2,200
-67% -$389K 0.1% 340
2014
Q1 		$599K Buy
+3,293
New +$652K 0.18% 171

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ellington Management Group's NKTR Position: Q2 2017 in Review

Ellington Management Group sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 3,307 shares — an estimated $1.16M sold.

Ellington Management Group first reported a position in NKTR in Q1 2014 and held it in 5 quarters. The position peaked at $1.16M in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

  • Ellington Management Group reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Ellington Management Group sold 3,307 Nektar Therapeutics shares in Q2 2017, an estimated $1.16M.
  • Ellington Management Group first reported a position in Nektar Therapeutics in Q1 2014 and held it in 5 quarters.
  • Ellington Management Group's Nektar Therapeutics position peaked at $1.16M in Q1 2017.
  • 197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Ellington Management Group's 13F filing for Q2 2017, filed 14 Aug 2017.